Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

BridgeBio Pharma (BBIO) Restructuring Costs: 2022-2024

Historic Restructuring Costs for BridgeBio Pharma (BBIO) over the last 3 years, with Dec 2024 value amounting to $15.6 million.

  • BridgeBio Pharma's Restructuring Costs rose 91.32% to $8.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $14.9 million, marking a year-over-year increase of 27.80%. This contributed to the annual value of $15.6 million for FY2024, which is 96.88% up from last year.
  • BridgeBio Pharma's Restructuring Costs amounted to $15.6 million in FY2024, which was up 96.88% from $7.9 million recorded in FY2023.
  • In the past 5 years, BridgeBio Pharma's Restructuring Costs registered a high of $43.8 million during FY2022, and its lowest value of $7.9 million during FY2023.
  • For the 3-year period, BridgeBio Pharma's Restructuring Costs averaged around $22.4 million, with its median value being $15.6 million (2024).
  • Its Restructuring Costs has fluctuated over the past 5 years, first tumbled by 81.89% in 2023, then soared by 96.88% in 2024.
  • Yearly analysis of 3 years shows BridgeBio Pharma's Restructuring Costs stood at $43.8 million in 2022, then plummeted by 81.89% to $7.9 million in 2023, then soared by 96.88% to $15.6 million in 2024.